VEGFA and non-small cell lung carcinoma: <h4>Introduction</h4>Ivonescimab (AK112), a novel bispecific antibody targeting PD-1 and VEGF, has emerged as a promising therapeutic agent in the treatment of non-small cell lung cancer (NSCLC).